A randomized phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.

被引：0
|
作者：
Kim, Hyung-Don
Yoo, Changhoon
Ryu, Min-Hee
Kang, Yoon-Koo
机构：
[1] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[2] Univ Uslan, Asan Med Ctr, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11538
引用
收藏
页数：1
相关论文
共 50 条
  • [11] A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors
    Bendell, Johanna C.
    Bauer, Todd M.
    Lamar, Ruth
    Joseph, Mathew
    Penley, William
    Thompson, Dana S.
    Spigel, David R.
    Owera, Rami
    Lane, Cassie M.
    Earwood, Chris
    Burris, Howard A., III
    CANCER INVESTIGATION, 2016, 34 (06) : 265 - 270
  • [12] Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group
    Park, S. H.
    Ryu, M. H.
    Ryoo, B. Y.
    Im, S. A.
    Kwon, H. C.
    Lee, S. S.
    Park, S. R.
    Kang, B. Y.
    Kang, Y. K.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (06) : 2377 - 2383
  • [13] Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group
    S. H. Park
    M. H. Ryu
    B. Y. Ryoo
    S. A. Im
    H. C. Kwon
    S. S. Lee
    S. R. Park
    B. Y. Kang
    Y. K. Kang
    Investigational New Drugs, 2012, 30 : 2377 - 2383
  • [14] A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report.
    Heinrich, Michael C.
    vonMehren, Margaret
    Demetri, George D.
    Fletcher, Jonathan A.
    Sun, Jichao
    Hodgson, J. Graeme
    Rivera, Victor M.
    Turner, Christopher D.
    George, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [15] A Phase I study of ZD6474, an oral VEGF receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Hurwitz, HI
    Eckhardt, SG
    Holden, SN
    Basser, R
    Deboer, R
    Rosenthal, M
    Rischin, D
    Swaisland, H
    Barge, A
    McKinley, M
    Wheeler, C
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3654S - 3654S
  • [16] Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study
    Toulmonde, Maud
    Blay, Jean-Yves
    Bouche, Olivier
    Mir, Olivier
    Penel, Nicolas
    Isambert, Nicolas
    Duffaud, Florence
    Bompas, Emmanuelle
    Esnaud, Thomas
    Boidot, Romain
    Geneste, Damien
    Ghiringhelli, Francois
    Lucchesi, Carlo
    Bellera, Carine A.
    Le Loarer, Francois
    Italiano, Antoine
    CLINICAL CANCER RESEARCH, 2019, 25 (15) : 4611 - 4615
  • [17] Ponatinib efficacy and safety in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure: Results from a phase 2 study.
    Heinrich, Michael C.
    von Mehren, Margaret
    Demetri, George D.
    Fletcher, Jonathan A.
    Sun, Jichao G.
    Kerstein, David
    Conlan, Maureen G.
    George, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [18] Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
    Kollmannsberger, Christian K.
    Sharma, Sunil
    Shapiro, Geoffrey
    Chi, Kim N.
    Christensen, James
    Tassell, Vanessa Roberts
    Chao, Richard C.
    Faltaos, Demiana
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [19] A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies
    Das, Millie
    Padda, Sukhmani K.
    Frymoyer, Adam
    Molina, Julian
    Adjei, Alex
    Lensing, Janet L.
    Miles, Dale
    Sikic, Branimir I.
    Wakelee, Heather A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (03) : 541 - 550
  • [20] A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies
    Millie Das
    Sukhmani K. Padda
    Adam Frymoyer
    Julian Molina
    Alex Adjei
    Janet L. Lensing
    Dale Miles
    Branimir I. Sikic
    Heather A. Wakelee
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 541 - 550
12345